A Phase I, Open Label, Multicenter, Dose-escalation Study of BI 907828 in Adult Patients With Wild-type TP53 Enriched Advanced Solid Tumors and Expansion in Patients With MDM2 Amplified Advanced Solid Tumors.

Trial Profile

A Phase I, Open Label, Multicenter, Dose-escalation Study of BI 907828 in Adult Patients With Wild-type TP53 Enriched Advanced Solid Tumors and Expansion in Patients With MDM2 Amplified Advanced Solid Tumors.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Aug 2018

At a glance

  • Drugs BI 907828 (Primary)
  • Indications Brain metastases; Glioblastoma; Non-small cell lung cancer; Soft tissue sarcoma; Solid tumours; Urogenital cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 06 Jun 2018 Planned End Date changed from 24 Apr 2023 to 13 Jun 2023.
    • 06 Jun 2018 Status changed from not yet recruiting to recruiting.
    • 15 May 2018 Planned End Date changed from 16 Aug 2023 to 24 Apr 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top